<DOC>
	<DOCNO>NCT00438360</DOCNO>
	<brief_summary>The study evaluate efficacy cyclosporine 2 , 5 mg/kg/day bid ( i.e . bis day ) , administer twice week compare continuous administration , patient chronic plaque psoriasis .</brief_summary>
	<brief_title>Efficacy Safety Cyclosporine A Microemulsion Maintenance Patients With Chronic Plaque Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<criteria>Inclusion criterion : Outpatients 18 year age old ( max 65 year ) Patients chronic plaque psoriasis disease remission ( i.e . PASI ≤75 % PASI cyclosporine continuous treatment course ) enter maintenance period Disease remission obtain cyclosporine systemic therapy ( maximum dose 5 mg/kg/day ) &gt; 8 week &lt; 16 week PASI still &lt; 75 % PASI cyclosporine continuous treatment course , randomization study treatment ( 8±2 day disease remission ) Exclusion criterion : Abnormal renal function ( creatinine ≥ 10 % upper limit reference range ) Severe chronic degenerative disease Severe uncontrolled hypertension Body weigh &gt; 110 kg Abnormal liver function Hyperkalemia hyperuricemia Clinically significant impairment hematopoietic cardiovascular function Concomitant therapy nephrotoxic medication Patients malignancy history malignancy Females childbearing potential planning become pregnant , pregnant and/or lactating , unwilling use effective mean contraception Clinically significant uncontrolled bacterial , viral fungal infection Evidence drug and/or alcohol abuse</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>Cyclosporine , chronic plaque psoriasis , intermittent therapy</keyword>
</DOC>